RhumbLine Advisers’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-85,756
| Closed | -$292K | – | 2991 |
|
|
2018
Q3 | $292K | Sell |
85,756
-6,075
| -7% | -$21.9K | ﹤0.01% | 2525 |
|
|
2018
Q2 | $345K | Buy |
91,831
+8,545
| +10% | +$41.6K | ﹤0.01% | 2462 |
|
|
2018
Q1 | $341K | Sell |
83,286
-1,020
| -1% | -$4.75K | ﹤0.01% | 2374 |
|
|
2017
Q4 | $392K | Sell |
84,306
-16,735
| -17% | -$92.2K | ﹤0.01% | 2345 |
|
|
2017
Q3 | $717K | Buy |
101,041
+1,330
| +1% | +$9.56K | ﹤0.01% | 2148 |
|
|
2017
Q2 | $721K | Buy |
99,711
+335
| +0.3% | +$2.09K | ﹤0.01% | 2127 |
|
|
2017
Q1 | $612K | Buy |
99,376
+6,750
| +7% | +$37K | ﹤0.01% | 2165 |
|
|
2016
Q4 | $543K | Sell |
92,626
-1,448
| -2% | -$7.91K | ﹤0.01% | 2184 |
|
|
2016
Q3 | $500K | Sell |
94,074
-2,950
| -3% | -$15.9K | ﹤0.01% | 2204 |
|
|
2016
Q2 | $642K | Sell |
97,024
-10,287
| -10% | -$57.5K | ﹤0.01% | 2036 |
|
|
2016
Q1 | $501K | Sell |
107,311
-90
| -0.1% | -$359 | ﹤0.01% | 2221 |
|
|
2015
Q4 | $542K | Buy |
107,401
+7,770
| +8% | +$36.9K | ﹤0.01% | 2196 |
|
|
2015
Q3 | $351K | Sell |
99,631
-65
| -0.1% | -$435 | ﹤0.01% | 2443 |
|
|
2015
Q2 | $995K | Sell |
99,696
-3,125
| -3% | -$33.5K | ﹤0.01% | 1876 |
|
|
2015
Q1 | $1.31M | Buy |
102,821
+21,610
| +27% | +$278K | ﹤0.01% | 1693 |
|
|
2014
Q4 | $1.15M | Sell |
81,211
-1,245
| -2% | -$19.3K | ﹤0.01% | 1709 |
|
|
2014
Q3 | $1.13M | Sell |
82,456
-3,665
| -4% | -$56.1K | ﹤0.01% | 1678 |
|
|
2014
Q2 | $1.32M | Buy |
86,121
+945
| +1% | +$13.4K | ﹤0.01% | 1647 |
|
|
2014
Q1 | $1.45M | Buy |
85,176
+5,230
| +7% | +$78.9K | ﹤0.01% | 1558 |
|
|
2013
Q4 | $1.03M | Buy |
79,946
+4,380
| +6% | +$52.3K | ﹤0.01% | 1786 |
|
|
2013
Q3 | $763K | Sell |
75,566
-431
| -0.6% | -$3.84K | ﹤0.01% | 1952 |
|
|
2013
Q2 | $568K | Buy |
+75,997
| New | +$594K | ﹤0.01% | 2162 |
|
RhumbLine Advisers's KERX Position: Q4 2018 in Review
RhumbLine Advisers sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 85,756 shares — an estimated $292K sold.
RhumbLine Advisers first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $1.45M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- RhumbLine Advisers reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- RhumbLine Advisers sold 85,756 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $292K.
- RhumbLine Advisers first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- RhumbLine Advisers's Keryx Biopharmaceuticals Inc position peaked at $1.45M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.